• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Can Stoke Therapeutics (STOK) Justify Its Valuation Following The Phase 3 EMPEROR Update?

    Simply Wall St·07/10/2026 12:30:36
    Listen to the news

    Stoke Therapeutics (STOK) stock is back in focus after the company completed enrollment in its Phase 3 EMPEROR study for zorevunersen in Dravet syndrome, outlining key efficacy endpoints and a detailed U.S. regulatory timeline.

    See our latest analysis for Stoke Therapeutics.

    The latest EMPEROR update comes after Stoke Therapeutics was recently removed from several Russell indices. The stock still shows a 1-year total shareholder return of 172.67% and a 3-year total shareholder return of 222.18%. In addition, the 30-day share price return of 11.78% against a 90-day share price decline of 4.37% suggests that momentum has picked up again in the short term.

    If you are watching how clinical milestones can shift sentiment in healthcare, it might be a good moment to scan for other opportunities across 40 healthcare AI stocks

    After a sharp run alongside the EMPEROR update and index removal, Stoke Therapeutics now asks a simple question of anyone looking at the stock today: does the current price still leave enough upside to justify the clinical and earnings risk?

    Most Popular Narrative: 27.2% Undervalued

    Against a last close of $32.83, the most followed narrative for Stoke Therapeutics points to a fair value of $45.10, which implies material upside in that framework and puts extra weight on how credible the underlying assumptions look.

    The shift toward disease-modifying therapies in severe epilepsies raises the regulatory and evidentiary bar. Any delay, additional data requirements, or failure to show clear differentiation versus emerging competitors could push out potential launch timing and limit peak revenue.

    Read the complete narrative.

    Want to see what is sitting under that headline fair value for Stoke Therapeutics? The narrative leans on rapid revenue expansion, a sharp margin swing, and a future earnings multiple that is usually reserved for market leaders. Curious how those pieces fit together into one price target story?

    Result: Fair Value of $45.10 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, this Stoke Therapeutics narrative could be challenged if the Phase 3 EMPEROR trial fails to confirm earlier seizure and cognition signals, or if regulators require longer and more costly paths to approval.

    Find out about the key risks to this Stoke Therapeutics narrative.

    Next Steps

    If the mixed tone on Stoke Therapeutics has you weighing both the upside and the downside, take a closer look at the underlying data now and pressure test the balance of risks and rewards with the 2 key rewards and 1 important warning sign

    Looking for more investment ideas beyond Stoke Therapeutics?

    If Stoke Therapeutics has sharpened your focus on where risk and reward can meet, do not stop here. Broaden your watchlist before the next move passes you by.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.